standard]
MLLQLAWIFLSGLALTLAATNSTTIPDTFNISKAPVITKPGCPSKCGNLT
VPYPFGIGRGSGCGIDPWFELNCSNAFDPPRAYLGNIQIYDISDNQMRIS
NVMARRCYDRAGDVSQTNYASSDITGTPYSYSSLNKFTVLGCDDFALVTG
GGGRNFTSGCVSLCSRAEDVISGYCSGIGCCQTSLPKGLKFYLTDLSSLR
NHTGVSSFNPCSYAFLGEEQRFVFRGASDLSDPNFMQRVLTTVPIVLDWA
IGNLTCADAEKAADYACKANSYCVDSDTGLGGYRCSCNKGYDGNPYLDPG
CTDIDECADPNLNDCEKFMCINTLGGFNCSCPHGMYGDGREDGRGCNAYT
SEFPVMKVALGIGFGFLSLVIAVTWLYFSLKKRKIIKLREKFFQQNGGLL
LKQQISSNEGSVDQSTKIFTAEELEKATNNYADDRILGRGGYGTVYKGIL
PDNRIVAIKKSRVMDESQIEQFINEVVILTQVNHRNVVKLLGCCLESEVP
LLVYEYVSNGTLFEHIHNKGAMTWLSWENRLRIASEAAGALSYLHSAASI
PIIHRDVKSANILLDESYTAKISDFGASRLISLDQTEVTTLVQGTLGYLD
PEYFHSSQLTEKSDVYSFGVVLAELLTGKRPIDMERGQEERNLATYFIMA
VKENRLFQILEPRVVREGSLEQLQATAQLIKRCLHLNGEDRPTMKEVAME
LEGLRKFTKHPWAQQPVHHEESVGLLMSDQMGSADLYTAPITSADLYTVP
ISSYNSTGESSGQYSLNSTPSQMFFPHVNSPR
|
IPR000152; EGF-type aspartate/asparagine hydroxylation site IPR000719; Protein kinase, catalytic domain IPR000742; Epidermal growth factor-like, type 3 IPR001881; EGF-like calcium-binding IPR002290; S |